Hoofddorp, The Netherlands, 2 October 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced that the collaboration with Diego Mortillaro is terminated. The former CEO resigned due to personal reasons. Diego Mortillaro remains one of the major shareholders of the Company with a look-up engagement until December 2019.

Continue reading →